HAVN Life Sciences Inc.
HAVN
CNSX
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -12.33M | -13.55M | -18.44M | -17.83M | -17.59M |
| Total Depreciation and Amortization | 148.40K | 252.50K | 387.50K | 458.50K | 2.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.46M | 9.79M | 13.30M | 11.50M | 7.52M |
| Change in Net Operating Assets | 679.20K | 102.30K | -194.70K | -428.50K | -973.30K |
| Cash from Operations | -2.04M | -3.40M | -4.95M | -6.29M | -8.55M |
| Capital Expenditure | 0.00 | -13.40K | -14.00K | -83.50K | -109.40K |
| Sale of Property, Plant, and Equipment | 22.10K | 22.10K | 22.10K | 22.10K | -- |
| Cash Acquisitions | 0.00 | 0.00 | -159.10K | -972.80K | -1.04M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | -601.20K | -601.20K | -611.20K |
| Cash from Investing | 22.10K | 8.70K | -752.20K | -1.64M | -1.76M |
| Total Debt Issued | 137.70K | 421.50K | -- | -- | -- |
| Total Debt Repaid | -32.70K | -65.40K | -130.80K | -130.80K | -130.80K |
| Issuance of Common Stock | 2.00M | 2.00M | 2.03M | 2.03M | 523.30K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -354.70K | -354.70K | -354.70K | -334.70K | 0.00 |
| Cash from Financing | 1.38M | 1.56M | 1.22M | 1.23M | 311.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -640.80K | -1.83M | -4.48M | -6.70M | -9.99M |